Immunotoxins | Market Size, Share & Growth Report 2024-2030
The Immunotoxins Market Report is Segmented by Product Type (Monoclonal Antibody-Immunotoxins, Recombinant Immunotoxins, Conjugate Immunotoxins, Fusion Proteins, and Bispecific Immunotoxins), Application (Cancer Treatment, Autoimmune Diseases, Immunodeficiency Disorders, Inflammatory Disorders, and Infectious Diseases), Distribution Channel (Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies, and Others), Ingredient Type (Ricin, Diphtheria Toxin, Pseudomonas Exotoxin A, Staphylococcal Enterotoxin A, and Abrin).
Immunotoxins Market
Market Analysis
How the market stands today, and what is shaping it
The global immunotoxins market was estimated at approximately USD 159.9 million in 2024 and is projected to reach around USD 243.3 million by 2030, representing a CAGR of approximately 7.25% during 2024–2030, based on Core Market Research estimates. The market rests on a very small approved base. Three immunotoxins have been approved anywhere, and only tagraxofusp and denileukin diftitox-cxdl remain in active supply, both built on a diphtheria toxin payload fused to an interleukin ligand. Growth is supported by tagraxofusp's position as the only agent approved for blastic plasmacytoid dendritic cell neoplasm in both the United States and the European Union. The December 2025 United States launch of LYMPHIR and orphan designations covering these rare indications provide further support. Expansion is constrained by the boxed warning for capillary leak syndrome, by rare-disease patient numbers that cap absolute volume, and by the 2023 withdrawal of moxetumomab pasudotox for low clinical uptake. Competition is concentrated around individual assets rather than broad portfolios, with three corporate groups holding the commercialised products under differing ownership and regional licensing arrangements. Citius Oncology recorded USD 3.9 million in the quarter ended 31 December 2025, the category's first new commercial revenue since 2018.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Tagraxofusp remains the only agent approved for blastic plasmacytoid dendritic cell neoplasm in both the United States and the European Union, so newly diagnosed patients have no substitute therapy and each diagnosis converts directly into treatment demand.
- Removing domain II of Pseudomonas exotoxin A and silencing B-cell and T-cell epitopes through seven point mutations produced the PE24 payload used in LMB-100. That construct tolerates three to eight times the dose of first-generation SS1P in animal models, which is what makes next-generation candidates clinically testable.
- Orphan drug designation from both the FDA and the EMA for relapsed or refractory hairy cell leukaemia, and comparable rare-disease designations across these indications, shorten review and extend exclusivity, improving the economics sponsors apply to very small populations.
- Addition of denileukin diftitox-cxdl to the NCCN Clinical Practice Guidelines at Category 2A in September 2024 gave treating centres a consensus recommendation, and the separate permanent HCPCS J-code J9161 took effect on 1 April 2025, supplying the billing route roughly seven months later.
- Citius Oncology began United States sales of LYMPHIR in December 2025 and recorded USD 3.9 million in the quarter ended 31 December 2025, converting a dormant approval into active revenue and returning a third immunotoxin to commercial supply.
Market Challenges
- The boxed warning for capillary leak syndrome on tagraxofusp reports the event in 53% of patients, 65 of 122, with four deaths. Albumin monitoring and inpatient observation are required through the first cycle, where all but five reported events occurred, which restricts administration to centres equipped for that intensity of care.
- Neutralising antibodies developed in 95.7% of the moxetumomab pasudotox patients who tested anti-drug antibody positive, 67 of 70. The deimmunised next-generation construct LMB-100 still leaves most recipients without adequate drug levels by the third cycle, so the useful number of cycles is capped across product generations.
- AstraZeneca withdrew moxetumomab pasudotox from the United States market in July 2023 citing very low clinical uptake rather than safety or efficacy, showing that approval in a rare indication does not establish a commercially sustainable product.
- Blastic plasmacytoid dendritic cell neoplasm and relapsed or refractory cutaneous T-cell lymphoma are rare diseases, so the absolute number of treatable patients is small and revenue depends on price and duration of therapy rather than patient volume.
- The LYMPHIR pivotal study required CD25 expression on at least 20% of biopsied malignant cells by immunohistochemistry, so eligibility depends on biomarker testing that narrows the treatable share of an already small cutaneous T-cell lymphoma population.
Opportunities
- An investigator-initiated study evaluating LYMPHIR within lymphodepletion regimens before CAR-T therapy could position the agent as immune conditioning rather than as a lymphoma treatment, which may open a use base far larger than cutaneous T-cell lymphoma.
- A separate investigator-initiated study combining LYMPHIR with pembrolizumab in recurrent solid tumours may extend an agent currently limited to a rare haematological indication into solid tumour settings where patient numbers are substantially higher.
- The chimeric Pseudomonas exotoxin and diphtheria toxin scaffold reported by Friedrich Alexander University Erlangen-Nuremberg in August 2026 achieved roughly four-fold higher internalisation and could rescue targets such as CD138 where Pseudomonas-based constructs have underperformed.
- Citius has stated an intention to explore LYMPHIR in peripheral T-cell lymphoma, an indication already approved for denileukin diftitox in Japan, which may support a label extension informed by existing Japanese clinical experience.
- Engineering approaches under investigation to reduce immunogenicity and extend half-life, including PEGylation, epitope modification and synthetic vaccine particles carrying rapamycin, have the potential to lift the ceiling on cycles per patient that currently limits revenue per course.
Trends and Insights
Key market trends shaping the industry landscape
Deimmunisation Becomes the Default Design
High impactMid-termNew immunotoxin constructs are engineered from the outset to suppress B-cell and T-cell epitopes rather than relying on unmodified bacterial toxin domains.
Insight: Deimmunisation has raised the tolerable dose rather than removed the ceiling. Every patient given LMB-100 still forms neutralising antibodies and most lose effective exposure after the second cycle, so revenue per patient course stays capped and sponsors are pushed toward combination and conditioning roles.
Movement From Monotherapy to Combination Regimens
High impactMid-termSponsors are testing approved immunotoxins inside combination regimens rather than as single agents, including new phase 2 tagraxofusp combination data in blastic plasmacytoid dendritic cell neoplasm presented at the ASCO Annual Meeting in May 2026.
Insight: Combination positioning allows an agent confined to a rare salvage setting to be evaluated earlier in the treatment pathway, which changes the addressable population without requiring a new molecule.
Commercial Viability Replaces Approval as the Gating Test
High impactShort-termSponsors are treating launch economics, guideline inclusion and reimbursement coding as the decisive hurdle, following the withdrawal of moxetumomab pasudotox from the United States market in July 2023 for low uptake.
Insight: Approval no longer predicts availability in this category, so forecasting must account for products that hold a licence but generate no supply, as occurred in the European Union where moxetumomab pasudotox was never marketed.
Repositioning Toward Immune Conditioning
Medium impactLong-termInterleukin-2 receptor directed agents are being examined for their capacity to deplete regulatory T cells ahead of cell therapy, rather than for direct tumour cytotoxicity.
Insight: If conditioning use is established, demand would follow the volume of cell therapy procedures rather than the incidence of cutaneous T-cell lymphoma, which is a structurally different and considerably larger demand base.
Toxin Domain Re-engineering Beyond Pseudomonas Exotoxin
Medium impactLong-termResearch groups are recombining domains across bacterial toxins, as in the chimeric construct pairing a Pseudomonas exotoxin furin cleavage site with diphtheria toxin catalytic and transport domains reported in August 2026.
Insight: Internalisation efficiency proved target dependent, improving cytotoxicity for CD138 and mesothelin but not CD22, indicating that payload selection will increasingly be matched to the individual target rather than standardised across a platform.
Segment Analysis
Market segmentation by product type, application, distribution channel, ingredient type
The supplied categories are Monoclonal Antibody-Immunotoxins, Recombinant Immunotoxins, Conjugate Immunotoxins, Fusion Proteins and Bispecific Immunotoxins. Both agents in active supply are Fusion Proteins. Tagraxofusp joins interleukin-3 to a truncated diphtheria toxin, and denileukin diftitox joins interleukin-2 to diphtheria toxin. No revenue split by product type is published, so this category's standing rests on that count of two from two rather than on a measured share. Monoclonal Antibody-Immunotoxins are represented only by moxetumomab pasudotox, which fused a CD22-binding antibody fragment to Pseudomonas exotoxin PE38. It left the United States market in July 2023, so the category retains an approval history but no current product. All approved agents are recombinant proteins, so Recombinant Immunotoxins overlaps the other categories rather than forming a separate commercial cohort. Bispecific Immunotoxins have no approved product and appear only in research-stage constructs.
Geography Analysis
Regional market analysis
North America
North America is where every approved immunotoxin reached market first, and the only region with an active commercial launch in the forecast period. The FDA approved moxetumomab pasudotox on 13 September 2018 for relapsed or refractory hairy cell leukaemia after at least two prior lines. Tagraxofusp followed in December 2018 for blastic plasmacytoid dendritic cell neoplasm in adults and children aged two years and older. Denileukin diftitox-cxdl was approved on 7 August 2024 for adults with relapsed or refractory stage I to III cutaneous T-cell lymphoma after at least one prior systemic therapy. Stemline Therapeutics has marketed tagraxofusp in the United States since 2019. Citius Oncology launched LYMPHIR in December 2025 and reported USD 3.9 million for the quarter ended 31 December 2025. Access infrastructure is more developed than elsewhere: NCCN Category 2A listing came in September 2024, and HCPCS code J9161 took effect on 1 April 2025. The region also carries the counterexample, as AstraZeneca withdrew moxetumomab pasudotox in July 2023 for very low clinical uptake. No regional market size, revenue or growth figure for North America was identified in the sources reviewed for this report. The ranking therefore rests on documented regulatory and commercial concentration rather than on a measured regional series.
Europe
Europe shows a marked gap between regulatory approval and commercial supply. The European Commission authorised ELZONRIS in January 2021 as monotherapy for first-line treatment of adult blastic plasmacytoid dendritic cell neoplasm, held by the Menarini Group through Stemline Therapeutics. Moxetumomab pasudotox took the opposite path. It received European Union marketing authorisation on 8 February 2021, and that authorisation was withdrawn on 23 July 2021 at the request of AstraZeneca AB for commercial reasons. The product was never marketed in the European Union at all. Denileukin diftitox-cxdl has no European approval, and the Citius licence covering all markets except Japan and certain parts of Asia has so far been exercised only in the United States. Europe contributes research capability rather than commercial volume. A chimeric Pseudomonas exotoxin and diphtheria toxin construct achieving roughly four-fold higher internalisation was reported in August 2026 by Friedrich Alexander University Erlangen-Nuremberg in Germany.
Asia Pacific
Asia Pacific activity centres on Japan, under a rights structure separate from the rest of the world. Eisai received approval for Remitoro, denileukin diftitox (genetical recombination), on 23 March 2021. The indications are relapsed or refractory peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma. National Health Insurance Drug Price List entry followed on 19 May 2021, establishing reimbursed access. Approval rested on Phase II Study 205, which met its primary endpoint with an objective response rate of 36.1%. The agent originated with Ligand Pharmaceuticals, and Eisai retains exclusive development and marketing rights in Japan and Asia, which is why the Citius licence expressly excludes those territories. Japan is also the only market where denileukin diftitox carries a peripheral T-cell lymphoma indication alongside cutaneous T-cell lymphoma, a broader label than the United States approval. No immunotoxin approval has been identified elsewhere in the region.
Latin America
Latin America has no identified marketing authorisation for any of the three approved immunotoxins. Approvals for these agents are confined to the United States, the European Union and Japan. The only commercial launch in the forecast period, LYMPHIR in December 2025, went no further than the United States, even though the Citius licence nominally covers all markets except Japan and certain parts of Asia. Tagraxofusp remains the only approved therapy worldwide for blastic plasmacytoid dendritic cell neoplasm. Patients in the region therefore face a therapeutic gap that no substitute product can fill. Published clinical experience for the region is limited to isolated case reports rather than registry or reimbursement data. Regional demand is latent rather than commercial, and would depend on sponsors pursuing national registrations for indications with very small patient numbers.
Middle East & Africa
Middle East and Africa is the least commercially developed region for this market. As in Latin America, no marketing authorisation for tagraxofusp, denileukin diftitox or moxetumomab pasudotox has been identified there, and no sponsor has announced a launch. Infrastructure requirements compound the access gap. The tagraxofusp boxed warning for capillary leak syndrome requires albumin monitoring and inpatient observation during Cycle 1, which restricts administration to tertiary centres. Diagnosis is a further constraint. Blastic plasmacytoid dendritic cell neoplasm and relapsed or refractory cutaneous T-cell lymphoma are rare and need specialist haematopathology to identify, including immunohistochemistry for CD25 expression to establish denileukin diftitox-cxdl eligibility. Diagnosis rates rather than supply are therefore likely to be the first constraint on any future regional demand.
Competitive Landscape
Key players and market positioning analysis
Competition in the immunotoxins market is concentrated around individual assets rather than broad commercial portfolios. The currently commercialised approved products are associated with three principal corporate groups, with different ownership and regional licensing structures. They fall into three cohorts. The first is the integrated European pharmaceutical owner. The Menarini Group, through Stemline Therapeutics, holds tagraxofusp with FDA approval since December 2018, United States marketing since 2019 and European Commission authorisation since January 2021. It is the only participant with the same agent commercialised on both sides of the Atlantic. Its position rests on holding the sole approved therapy for blastic plasmacytoid dendritic cell neoplasm, and it is extending that position through combination data rather than new molecules, presenting phase 2 combination results at ASCO in May 2026. The second cohort is the single-asset specialist. Citius Pharmaceuticals, through its approximately 74.8% owned subsidiary Citius Oncology, holds a licence to denileukin diftitox-cxdl covering all markets except Japan and certain parts of Asia, and launched in the United States in December 2025. Its commercial positioning is centred on access and launch execution, while the underlying molecule is an established immunotoxin. It secured NCCN Category 2A inclusion in September 2024 and HCPCS code J9161 from 1 April 2025, both ahead of launch. The third cohort comprises regional rights holders and originators, whose economics differ from those of the commercial sellers. Eisai holds exclusive rights in Japan and Asia and markets Remitoro under a broader label covering peripheral as well as cutaneous T-cell lymphoma. Ligand Pharmaceuticals originated the agent and participates through licensing rather than supply. Large-capitalisation participation has contracted rather than expanded. AstraZeneca withdrew moxetumomab pasudotox from the United States market in July 2023 and let its European authorisation lapse in July 2021, and Innate Pharma returned its United States and European commercialisation rights to AstraZeneca. That leaves the category to smaller and more specialised owners. The decisive competitive factors are therefore not efficacy rankings but tolerability management, immunogenicity engineering and reimbursement access. Capillary leak syndrome was reported in 53% of tagraxofusp-treated patients, and neutralising antibodies in 95.7% of the moxetumomab pasudotox patients who tested antibody positive. These findings illustrate important tolerability and repeat-exposure constraints associated with the respective products. A key research-stage contributor is the National Cancer Institute's Center for Cancer Research, which is advancing deimmunised constructs such as the mesothelin-targeted LMB-100. Future competitive differentiation may increasingly depend on whether approved agents can be evaluated in combination and conditioning roles, because the rare-disease populations supporting current approvals are too small to sustain multiple commercial entrants.
Major Players
Leading companies in the market
Industry Developments
14 recorded developments
Citius Oncology reported USD 3.9 million of revenue from initial LYMPHIR sales for the fiscal quarter ended 31 December 2025, announced on 13 February 2026, the first commercial revenue recorded for a newly launched immunotoxin since 2018.
Menarini and Stemline Therapeutics presented new phase 2 tagraxofusp combination data in blastic plasmacytoid dendritic cell neoplasm at the ASCO Annual Meeting in May, delivered by Naveen Pemmaraju of The University of Texas MD Anderson Cancer Center.
Researchers at Friedrich Alexander University Erlangen-Nuremberg reported in August a chimeric fusion toxin combining a Pseudomonas exotoxin furin cleavage site with diphtheria toxin catalytic and transport domains, achieving approximately four-fold higher internalisation than Pseudomonas-based comparators.
Citius Oncology initiated the United States commercial launch of LYMPHIR in December, completing initial distributor sales nationwide and returning a third immunotoxin to active supply after the withdrawal of moxetumomab pasudotox.
The FDA approved LYMPHIR (denileukin diftitox-cxdl) on 7 August for adults with relapsed or refractory stage I to III cutaneous T-cell lymphoma after at least one prior systemic therapy. Study 302 supported it with a 36.2% objective response rate and an 8.7% complete response rate in 69 patients.
Denileukin diftitox-cxdl was added to the NCCN Clinical Practice Guidelines in Oncology in September at Category 2A for cutaneous T-cell lymphoma, providing the consensus recommendation that payers reference in coverage decisions.
AstraZeneca withdrew moxetumomab pasudotox from the United States market in July, citing very low clinical uptake rather than safety or efficacy concerns, and instructed clinicians not to initiate new treatment.
The European Commission approved ELZONRIS in January as monotherapy for first-line treatment of adult blastic plasmacytoid dendritic cell neoplasm, extending the CD123-directed franchise of Menarini and Stemline Therapeutics into the European Union.
Eisai obtained Japanese approval for Remitoro on 23 March for relapsed or refractory peripheral and cutaneous T-cell lymphoma, based on Phase II Study 205 with an objective response rate of 36.1%, and secured National Health Insurance listing on 19 May.
The European Commission withdrew the marketing authorisation for Lumoxiti on 23 July, granted only on 8 February of the same year, at AstraZeneca's request for commercial reasons; the product was never marketed in the European Union.
The FDA approved moxetumomab pasudotox on 13 September for relapsed or refractory hairy cell leukaemia after at least two prior lines, introducing the first CD22-directed immunotoxin built on a Pseudomonas exotoxin PE38 payload.
The FDA approved tagraxofusp in December for blastic plasmacytoid dendritic cell neoplasm in adults and children aged two years and older, creating the first and still the only approved therapy for that disease.
ONTAK was voluntarily withdrawn from the market because of manufacturing difficulties, removing the only approved immunotoxin for cutaneous T-cell lymphoma and demonstrating that fusion-toxin production quality is a commercial risk in its own right.
The FDA approved denileukin diftitox as ONTAK for cutaneous T-cell lymphoma, establishing the first commercially available immunotoxin and validating the interleukin-2 receptor as a therapeutic target.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Product Type
5.3 By Application
5.4 By Distribution Channel
5.5 By Ingredient Type
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Menarini Group
9.2 Eisai Co., Ltd.
9.3 Citius Pharmaceuticals, Inc.
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2024
Forecast Period: 2024 - 2030
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Menarini Group, Eisai Co., Ltd., Citius Pharmaceuticals, Inc. + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.